Trials / Completed
CompletedNCT00998881
Monotherapy Study of MP-513 in Patients With Type 2 Diabetes
A Phase III, Double-blind, Placebo Controlled, Monotherapy Study of MP-513 in Japanese Patients With Type 2 Diabetes Mellitus - Confirmative Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in patients with type 2 Diabetes for 12 weeks administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teneligliptin 20 mg | |
| DRUG | Placebo |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2009-10-21
- Last updated
- 2026-01-02
- Results posted
- 2014-02-21
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00998881. Inclusion in this directory is not an endorsement.